June 12, 2026 · Gynecologic oncology · DOI: 10.1016/j.ygyno.2026.06.003

Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study

Listen to this summary

The AdORN study aimed to evaluate the safety and efficacy of atezolizumab, an immune checkpoint inhibitor, in combination with neoadjuvant chemotherapy for patients with newly diagnosed advanced-stage epithelial ovarian cancer. The results indicated that the treatment was feasible, did not delay interval cytoreductive surgery, and showed promising response rates, with notable changes in immune markers associated with treatment response. However, the study faced early termination due to negative results from a related trial, limiting patient enrollment and further analysis.

Stéphanie Gaillard, Jack Parker, Gloria Broadwater, Linda Duska, Hope Knochenhauer, Kari Ring, Leah McNally, Paula S Lee, Brittany Davidson, Rebecca Previs, Haley Moss, Layne W Rogers, Yanwan Dai, Andrew Berchuck, Andrew B Nixon, John S Yi, Michael Bookman, Kouros Owzar, Jadee L Neff, Jose Conejo-Garcia, Angeles Alvarez Secord

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play